XTANDI: the first and only androgen receptor inhibitor-based regimen to demonstrate overall survival benefit in non-metastatic hormone-sensitive prostate cancer (nmHSPC) with high-risk biochemical ...

The probability of survival at 8 years was an unprecedented 78.9% with XTANDI plus leuprolide versus 69.5% with leuprolide, in men with non-metastatic hormone-sensitive prostate cancer with high-risk ...

What criteria do clinicians use to classify men as “high risk” among patients with biochemically recurrent nonmetastatic castration-sensitive prostate cancer? This is an ASCO Meeting Abstract from the ...

Based on EMBARK data, both enzalutamide monotherapy and combination therapy (with leuprolide) reduced the likelihood of distant metastasis in patients with high-risk biochemically recurrent prostate ...

The 8-year overall survival rate was 78.9% with enzalutamide-leuprolide and 69.5% with leuprolide alone. Treatment with enzalutamide plus leuprolide reduces the risk of death by more than 40% in ...

Differences in Patient-Reported Outcome Measures in Patients With Cancer Six Months Before Death All premenopausal patients who underwent first HSCT from June 2016 to January 2022 were included in ...

The proportion of patients with serum luteinizing hormone (LH) suppression to < 4 mIU/mL at 60 minutes following a GnRHa stimulation test at Week 24 was 94%, and the results were statistically ...

LUPRON DEPOT-3 MONTH 11.25mg prescription and dosage sizes information for physicians and healthcare professionals. Pharmacology, adverse reactions, warnings and side effects.

*Localized: T 1/2, NX or N0, and M0. ‡ Locally advanced: T3/4, NX or N0, and M0, or N1 and M0. ITT: Intention to treat; PSA: Prostate-specific antigen. Reproduced ...

CLAYTON, North Carolina (WTVD) -- Paying attention to your medical bills is crucial as you never know if you'll catch a mistake. Robert Roesemann has been receiving the same Lupron injection for 20 ...